OPK

Over the past six months, OPKO Health reported stronger-than-expected Q2 2026 financial results, with a narrower net loss and increased revenues, particularly a 59.8% surge in pharmaceutical revenues, leading to a rebound in shares and raised full-year guidance. The company announced a strategic pivot towards becoming a therapeutics-focused entity, emphasizing its promising early-stage clinical pipeline. In August 2026, OPKO Health expanded its strategic relationship with HealthCare Royalty through a $125 million non-dilutive notes issuance secured by Mazdutide royalty interests. The company participated in the Wells Fargo 21st Annual Healthcare Conference in September 2026, where it highlighted its shift towards a therapeutics company. As of October 9, 2026, OPKO Health's stock price was $1.64, having seen a decline of 10.29% over the past six months.